Table 4

Achieved response during the first 6 months of exposure to a biologic by involvement of organs (105 exposures to biologics in total)

Exposures to biologicsNasal or auricular chondritis, n (%)Joints, n (%)Sternal chondritis, 
n (%)
Ocular inflammation,
n (%)
Vestibular or cochlear manifestation,
n (%)
Respiratory manifestations,
n (%)
Overall (n=105)31/57 (54.4)28/74 (37.8)31/57 (54.4)12/17 (70.6)6/9 (66.6)27/38 (71.0)
TNF antagonists (n=60)15/34 (44.1)17/43 (39.5)16/24 (66.7)6/8 (75.0)5/8 (62.5)17/24 (70.8)
 Infliximab (n=20)4/9 (44.4)4/14 (28.56)2/7 (28.6)4/4 (100)1/3 (33.3)6/8 (75.0)
 Adalimumab (n=25)6/12 (50.0)8/16 (50.0)9/10 (90.0)2/4 (50.0)3/4 (75.0)7/10 (70.0)
 Etanercept (n=11)3/9 (33.3)4/10 (40)5/5 (100)1/1 (100)4/4 (100)
 Golimumab (n=3)2/3 (66.7)1/2 (50.0)0/1 (0)0/1 (0)
 Certolizumab (n=1)0/1 (0)0/1 (0)0/1 (0)0/1 (0)
Tocilizumab (n=17)7/9 (77.8)4/11 (36.4)7/8 (87.5)3/4 (75.0)6/6 (100.0)
Anakinra (n=15)4/8 (50.0)4/10 (40.0)2/3 (66.7)1/3 (33.3)1/1 (100.0)1/3 (33.3)
Rituximab (n=7)2/2 (100)1/4 (25.0)1/1 (100)2/2 (100)1/3 (33.3)
Abatacept (n=6)3/4 (75.0)2/6 (33.3)2/2 (100)2/2 (100)
  • TNF, tumour-necrosis factor.